00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
00:07 , Mar 7, 2019 |  BC Extra  |  Preclinical News

STING structures reveal target sites

A trio of papers co-led by Zhijian “James” Chen revealed the molecular structure of STING in complex with two factors in its signaling pathway and a new function -- autophagy induction. The findings, reported in...
01:17 , Feb 16, 2019 |  BC Extra  |  Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
23:28 , Feb 13, 2019 |  BC Week In Review  |  Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
20:26 , Feb 11, 2019 |  BC Extra  |  Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Lilly licenses Aduro's STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
02:11 , Dec 19, 2018 |  BC Extra  |  Company News

Lilly licenses Aduro’s STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
12:32 , Apr 3, 2018 |  BC Extra  |  Preclinical News

Lurie Prize awarded for cGAS-STING discovery

The Foundation for the National Institutes of Health (FNIH) announced Tuesday it has awarded this year's Lurie Prize in Biomedical Sciences to Zhijian “James” Chen for the discovery of the cytosolic DNA sensor cGAMP synthase...